SG10201802104QA - Pharmaceutical composition of s-ketamine hydrochloride - Google Patents

Pharmaceutical composition of s-ketamine hydrochloride

Info

Publication number
SG10201802104QA
SG10201802104QA SG10201802104QA SG10201802104QA SG10201802104QA SG 10201802104Q A SG10201802104Q A SG 10201802104QA SG 10201802104Q A SG10201802104Q A SG 10201802104QA SG 10201802104Q A SG10201802104Q A SG 10201802104QA SG 10201802104Q A SG10201802104Q A SG 10201802104QA
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
ketamine hydrochloride
ketamine
hydrochloride
pharmaceutical
Prior art date
Application number
SG10201802104QA
Inventor
Esther D G Basstanie
Johanna Bentz
Roger C A Embrechts
Nico Rudolph Niemeijer
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50687638&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201802104Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG10201802104QA publication Critical patent/SG10201802104QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG10201802104QA 2013-03-15 2014-03-14 Pharmaceutical composition of s-ketamine hydrochloride SG10201802104QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791237P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
SG10201802104QA true SG10201802104QA (en) 2018-05-30

Family

ID=50687638

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201507347QA SG11201507347QA (en) 2013-03-15 2014-03-14 Pharmaceutical composition of s-ketamine hydrochloride
SG10201802104QA SG10201802104QA (en) 2013-03-15 2014-03-14 Pharmaceutical composition of s-ketamine hydrochloride

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201507347QA SG11201507347QA (en) 2013-03-15 2014-03-14 Pharmaceutical composition of s-ketamine hydrochloride

Country Status (16)

Country Link
US (5) US20140275278A1 (en)
EP (2) EP3636251B1 (en)
KR (1) KR102217616B1 (en)
CN (2) CN111643449A (en)
AU (2) AU2014240102A1 (en)
BR (1) BR112015022972B1 (en)
CL (1) CL2015002736A1 (en)
CR (1) CR20150481A (en)
ES (2) ES2911466T3 (en)
MX (1) MX371392B (en)
MY (1) MY180526A (en)
NI (1) NI201500135A (en)
PE (1) PE20200404A1 (en)
PH (1) PH12015502013A1 (en)
SG (2) SG11201507347QA (en)
WO (1) WO2014152196A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3043785B1 (en) 2013-09-13 2021-08-25 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN106562952B (en) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 Use of ketamine in the treatment of major depressive disorder
WO2017139382A1 (en) * 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments
US20180177744A1 (en) * 2016-12-22 2018-06-28 Gary Jay Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
DK3505157T3 (en) 2017-12-29 2022-02-28 Celon Pharma Sa DRY POWDER-KETAMIN COMPOSITION FOR PULMONAL ADMINISTRATION IN THE TREATMENT OF RESISTANT DEPRESSION
AU2019262197A1 (en) 2018-05-04 2020-11-26 Perception Neuroscience, Inc. Methods of treating substance abuse
US11154537B2 (en) 2018-08-10 2021-10-26 Eleusis Therapeutics Us, Inc. Method of treatment for ketamine infusion
EP3628313A1 (en) 2018-09-28 2020-04-01 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration
AU2020231172A1 (en) 2019-03-05 2021-09-23 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
JP2022542746A (en) 2019-05-31 2022-10-07 セロン ファーマ エス．アー． Electronically Supervised Administration of Pharmaceutical Compositions
DK3976012T3 (en) 2019-05-31 2024-04-15 Afyx Dev A/S INTRANASAL ADMINISTRATION OF KETAMINE IN PATIENTS WITH CLUSTER HEADACHE
EP3976145A1 (en) 2019-05-31 2022-04-06 Celon Pharma S.A. An inhaler for electronically supervised parenteral administration of a pharmaceutical composition
TW202135787A (en) 2019-12-12 2021-10-01 比利時商健生藥品公司 Esketamine formulations and methods for preparation and storage
CN114306218B (en) * 2020-09-30 2023-11-10 四川普锐特药业有限公司 Transmucosal administration R-ketamine pharmaceutical composition meeting pharmaceutical bacteriostasis requirements
CN113813250B (en) * 2021-07-21 2023-05-05 广州新济药业科技有限公司 Pharmaceutical composition containing ketamine and preparation method and application thereof
WO2023207729A1 (en) * 2022-04-26 2023-11-02 宜昌人福药业有限责任公司 Esketamine liquid preparation and use thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (en) 1969-12-19 1973-03-31 Bristol Myers Co Process for the resolution of racemic 2- (o-chlorophenyl) -2-methylaminocyclohexanone into the optically active isomers
JPS632932A (en) * 1986-06-23 1988-01-07 Teijin Ltd Powdery composition for nasal administration
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
DE4312016A1 (en) * 1993-04-13 1994-10-20 Goedecke Ag Stable ketamine solutions
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
AU733284B2 (en) 1995-02-24 2001-05-10 Stuart L. Weg Nasal and ocular administration of ketamine to manage pain and for detoxification
CA2230690C (en) 1995-08-30 2008-12-23 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
FR2739294B1 (en) 1995-09-29 1998-01-16 Lhd Lab Hygiene Dietetique NASAL SAFETY TIP
DE19619665C2 (en) 1996-05-15 2001-03-08 Goedecke Ag Racemate separation of ketamine
DE19723133A1 (en) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Discharge device for media
FR2764807B1 (en) 1997-06-18 1999-08-20 Valois Sa NASAL DISPENSING DEVICE FOR A FLUID OR POWDERY PRODUCT
BR9912395A (en) * 1998-07-24 2001-10-16 Seo Hong Yoo Preparation of dosage forms of clear aqueous solution with bile acids
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
EP1103256A1 (en) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Use of ketamine for the treatment of neuroendocrine immune dysfunction und algogenic psychosyndrome
US6572849B2 (en) 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
WO2004010932A2 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
EP1567145B1 (en) 2002-11-18 2009-06-03 Yaupon Therapeutics, Inc. Analgesic uses of (s)-norketamine
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US8082173B2 (en) 2003-05-22 2011-12-20 Cecil Kost Drug sample fulfillment architecture
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20060223788A1 (en) 2005-03-29 2006-10-05 Cathcart Clifton H Analgesic composition for topical use
EP1885414B1 (en) 2005-06-01 2012-11-21 SHL Group AB Device for delivering medicament
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
KR20090029690A (en) 2006-03-22 2009-03-23 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 Intranasal administration of ketamine to treat depression
WO2007123945A2 (en) 2006-04-21 2007-11-01 Aradigm Corporation Mechanical single dose intrapulmonary drug delivery devices
JP2009538331A (en) 2006-05-22 2009-11-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド Treatment for depression disorders
DE102007009888A1 (en) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Use of S-(+)-ketamine for treating depression, which is therapy-refractive depression, preferably depressive episode, relapsing disorder and bipolar affective disorder
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
US8710070B2 (en) 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
BRPI0911945A2 (en) * 2008-05-13 2015-10-13 Clarassance Inc recombinant human cc10 and its compositions for use in the treatment of nasal rhinitis
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
PL2582366T3 (en) 2010-06-15 2016-04-29 Gruenenthal Gmbh Pharmaceutical combination for the treatment of pain
WO2013003669A2 (en) 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
CN104395283A (en) 2011-10-14 2015-03-04 美国政府健康及人类服务部 The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain
KR102035877B1 (en) 2011-11-14 2019-10-23 알파시그마 에스.피.에이. Assays for selecting a treatment regimen for a subject with depression and methods for treatment
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
CN104519878A (en) 2012-03-12 2015-04-15 詹森药业有限公司 Esketamine for treatment of treatment-refractory or treatment-resistant depression
AU2016203771A1 (en) 2012-03-13 2016-06-23 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
WO2013149102A1 (en) 2012-03-30 2013-10-03 The General Hospital Corporation Compositions comprising scopolamine and ketamine in the treatment of depression
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
MX2015002378A (en) 2012-08-23 2015-09-25 Stuart L Weg Anxiolytic composition, formulation and method of use.
FR2994844B1 (en) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris GELIFYING FORMULATION BASED ON KETAMINE
NZ619257A (en) 2012-10-08 2015-07-31 Auckland Uniservices Ltd Ketamine derivatives
ES2484068B1 (en) 2013-02-08 2015-04-16 Ana MÍNGUEZ MARTÍ A pharmaceutical composition containing ketamine and amitriptyline
DK2983787T3 (en) 2013-04-12 2020-01-06 Icahn School Med Mount Sinai Procedure for the treatment of post-traumatic stress disorder
WO2015031410A1 (en) 2013-08-26 2015-03-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
EP3043785B1 (en) 2013-09-13 2021-08-25 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
US9569220B2 (en) 2013-10-06 2017-02-14 Synopsys, Inc. Processor branch cache with secondary branches
CN103705909A (en) 2013-12-16 2014-04-09 陈镜伊 Drug for painless induced abortion
WO2015101693A1 (en) 2013-12-31 2015-07-09 Servicio Andaluz De Salud Combined preparations and compositions for the treatment of oropharyngeal pain
CA2936809A1 (en) 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
WO2015158854A1 (en) 2014-04-17 2015-10-22 Develco Pharma Schweiz Ag Oral dosage form of ketamine
JP6429898B2 (en) 2014-05-04 2018-11-28 フイルメニツヒ ソシエテ アノニムＦｉｒｍｅｎｉｃｈ Ｓａ Flavored food and beverage products
FR3023188B1 (en) 2014-07-04 2016-08-19 Aptar France Sas DEVICE FOR DISPENSING FLUID PRODUCT.
MX2017001908A (en) 2014-08-13 2017-08-08 Janssen Pharmaceutica Nv Method for the treatment of depression.
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
EP3240422A1 (en) 2014-12-31 2017-11-08 Icahn School of Medicine at Mount Sinai Method of maintaining the anti-depressant effect of ketamine with lithium
CN104798728A (en) 2015-05-08 2015-07-29 南京中医药大学 Creation method and applications of postpartum depression animal models
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20180296478A1 (en) 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
US20180042936A1 (en) 2016-03-18 2018-02-15 Genomind, Inc. Maintenance therapy using tianeptine
CN117531017A (en) 2017-12-22 2024-02-09 詹森药业有限公司 Esketamine for treating depression

Also Published As

Publication number Publication date
MX2015012617A (en) 2016-06-21
PE20200404A1 (en) 2020-02-26
NI201500135A (en) 2016-03-16
US11446260B2 (en) 2022-09-20
AU2019200424A8 (en) 2019-02-21
ES2911466T3 (en) 2022-05-19
CN111643449A (en) 2020-09-11
WO2014152196A1 (en) 2014-09-25
EP2968122B1 (en) 2019-08-28
US20190117591A1 (en) 2019-04-25
KR102217616B1 (en) 2021-02-19
KR20150132381A (en) 2015-11-25
EP3636251B1 (en) 2022-01-19
BR112015022972A2 (en) 2017-07-18
US20200069612A1 (en) 2020-03-05
AU2014240102A1 (en) 2015-09-17
CN105073096A (en) 2015-11-18
MY180526A (en) 2020-12-01
MX371392B (en) 2020-01-28
PH12015502013B1 (en) 2016-01-11
US20140275278A1 (en) 2014-09-18
EP3636251A1 (en) 2020-04-15
CL2015002736A1 (en) 2016-03-28
US20140274981A1 (en) 2014-09-18
AU2019200424A1 (en) 2019-02-14
EP2968122A1 (en) 2016-01-20
AU2019200424B2 (en) 2020-05-14
CR20150481A (en) 2015-10-26
SG11201507347QA (en) 2015-10-29
BR112015022972B1 (en) 2023-02-14
PH12015502013A1 (en) 2016-01-11
ES2755809T3 (en) 2020-04-23
US20230241009A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
IL288961A (en) Pharmaceutical compositions
SG11201507347QA (en) Pharmaceutical composition of s-ketamine hydrochloride
SG10201802106TA (en) Pharmaceutical composition of s-ketamine hydrochloride
HUE046964T2 (en) Combined pharmaceutical composition
PL2943181T3 (en) Pharmaceutical compositions
IL243608A0 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
PL3043778T3 (en) Pharmaceutical compositions containing refametinib
HK1213182A1 (en) Pharmaceutical composition for external application
ZA201408333B (en) Pharmaceutical compositions
EP2990038A4 (en) Solid pharmaceutical composition
PL2991618T3 (en) Stable high strength pharmaceutical composition of levoleucovorin
IL240875A0 (en) Heterocyclic compounds and pharmaceutical compositions containing them
SG11201601477VA (en) Pharmaceutical composition
HK1204916A1 (en) Pharmaceutical application of anhydroicaritin
HRP20171888T1 (en) Pharmaceutical compositions
HUP1300496A2 (en) Stable pharmaceutical composition
HK1220143A1 (en) Pharmaceutical composition
GB201304699D0 (en) Pharmaceutical compositions
GB201321497D0 (en) Pharmaceutical compositions
GB201304625D0 (en) New pharmaceutical composition
GB201312851D0 (en) Pharmaceutical compositions